식물성 및 식물 유래 의약품 시장 : 시장 규모, 점유율 및 성장 분석 - 제품 유형별, 원료별, 약제 클래스별, 용도별, 투여 경로별, 최종 사용자별, 지역별 업계 예측(2026-2033년)

Global Botanical And Plant Derived Drugs Market size was valued at USD 38.70 Billion in 2024 and is poised to grow from USD 41.99 Billion in 2025 to USD 80.65 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The regulatory approval of plant-based products is driving significant growth in the botanical and plant-derived drugs market, instilling confidence among investors and healthcare professionals. This formal recognition by regulatory bodies paves the way for reimbursement opportunities, fostering research investments and accelerating product development timelines. Notably, the validation of cannabinoids for specific medical applications has prompted a surge in clinical trials exploring their therapeutic potential in various fields, including dermatology and oncology. Consequently, pharmaceutical companies are forming partnerships with agricultural technology firms for material sourcing, while insurers are increasingly covering these innovative therapies. This development unlocks new revenue streams and enhances accessibility to these treatments for patients worldwide, reflecting a transformative shift in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Botanical And Plant Derived Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Botanical And Plant Derived Drugs Market Segments Analysis

Global botanical and plant derived drugs market is segmented by product type, source, drug class, application, route of administration, end user and region. Based on product type, the market is segmented into botanical drugs and plant-derived drugs. Based on source, the market is segmented into medicinal plants, herbs, flowers & fruits, roots & rhizomes and others. Based on drug class, the market is segmented into anticancer drugs, anti-inflammatory drugs, cardiovascular drugs, antimicrobial drugs, CNS drugs and others. Based on application, the market is segmented into oncology, cardiovascular disorders, infectious diseases, neurological disorders, pain management and others. Based on route of administration, the market is segmented into oral, topical, injectable and others. Based on end user, the market is segmented into hospitals, specialty clinics, pharmaceutical companies and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Botanical And Plant Derived Drugs Market

The rising consumer interest in natural and plant-based remedies propels pharmaceutical companies to delve deeper into herbal sources, aiming to diversify their portfolios with more plant-derived medicines. Many patients, prioritizing their health and seeking alternatives to synthetic drugs, perceive these natural options as safer and more beneficial for holistic well-being. This escalating demand prompts manufacturers to invest heavily in the research and development of plant-based active ingredients. Consequently, healthcare providers are more inclined to incorporate herbs into treatment plans, fostering opportunities to prescribe these natural products. As a result, manufacturers experience heightened interest from potential investors and partners, leading to collaborative efforts that enhance product launches and drive overall market growth.

Restraints in the Global Botanical And Plant Derived Drugs Market

The Global Botanical and Plant-Derived Drugs market faces significant challenges due to rigorous clinical validation requirements for botanical medicines, which demand comprehensive safety and efficacy testing. This extensive testing process prolongs product development timelines and escalates costs for manufacturers. Additionally, the intricate nature of phytochemistry calls for diverse analytical testing methods and larger sample sizes, intensifying regulatory hurdles for introducing new plant-based treatments. Consequently, smaller, innovative companies with limited resources may be deterred from entering the market with new botanical options. This slow rate of product introduction not only hampers market growth but also diminishes investor confidence in emerging ventures.

Market Trends of the Global Botanical And Plant Derived Drugs Market

The Global Botanical and Plant Derived Drugs market is witnessing a significant trend driven by the acceleration of plant genomics. Innovations in genomic research and high-throughput sequencing technologies are enabling companies to rapidly identify and develop bioactive compounds. This transformation is complemented by advancements in synthetic biology, allowing the replication of intricate plant pathways in microbial hosts, thereby diminishing reliance on traditional agricultural sources. This shift enhances supply chain stability across diverse therapeutic areas and encourages venture capital investment, fosters collaborations between biotech firms and academic institutions, and drives large pharmaceutical companies to integrate plant-based compounds into their research, ultimately broadening the potential for sustainable pharmaceuticals.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology

Global Botanical and Plant Derived Drugs Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Botanical Drugs
• Plant-Derived Drugs

Global Botanical and Plant Derived Drugs Market Size by Source & CAGR (2026-2033)

• Market Overview
• Medicinal Plants
• Herbs
• Flowers & Fruits
• Roots & Rhizomes
• Others

Global Botanical and Plant Derived Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Anticancer Drugs
• Anti-Inflammatory Drugs
• Cardiovascular Drugs
• Antimicrobial Drugs
• CNS Drugs
• Others

Global Botanical and Plant Derived Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Disorders
• Infectious Diseases
• Neurological Disorders
• Pain Management
• Others

Global Botanical and Plant Derived Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Injectable
• Others

Global Botanical and Plant Derived Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Pharmaceutical Companies
• Research Institutes

Global Botanical and Plant Derived Drugs Market Size & CAGR (2026-2033)

• North America (Product Type, Source, Drug Class, Application, Route of Administration, End User)
  • US
  • Canada
• Europe (Product Type, Source, Drug Class, Application, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Source, Drug Class, Application, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Source, Drug Class, Application, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Source, Drug Class, Application, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indena S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Schwabe Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bionorica SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tilray Brands, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhytoTech Therapeutics Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aboca S.p.A. Societa Agricola
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Martin Bauer Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euromed S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hunan Nutramax Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xi'an Jiaotong Pharmaceuticals Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sami-Sabinsa Group Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Himalaya Global Holdings Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yunnan Baiyao Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tasly Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediHerb Pty Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CK Life Sciences International Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PuraPharm Corporation Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations